Finance

Lists
Why is GOVX down 4,66%?
Dive Deeper
GOVX:NASDAQ
Geovax Labs Inc
0,30 US$
-4,66%
(-0,015) 1D
6 ოქტ, 12:50:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GOVX...
Open
0,32 US$
High
0,33 US$
Low
0,28 US$
Mkt. cap
2,77 მლნ.
Avg. vol.
889,21 ათ.
Volume
1,28 მლნ.
52-wk high
15,75 US$
52-wk low
0,28 US$
EPS
-13,92 US$
Beta
3,69
Shares outstanding
10,10 მლნ.
No. of employees
19
Open
0,32 US$
High
0,33 US$
Low
0,28 US$
Mkt. cap
2,77 მლნ.
Avg. vol.
889,21 ათ.
Volume
1,28 მლნ.
52-wk high
15,75 US$
52-wk low
0,28 US$
EPS
-13,92 US$
Beta
3,69
Shares outstanding
10,10 მლნ.
No. of employees
19
News stories
From web sources and news partners
Profile
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated. Wikipedia
About Geovax Labs Inc
CEOდავიდ ეი დოდ
Employees19
Founded1988
Headquartersატლანტა, ჯორჯია, ამერიკის შეერთებული შტატები
Sector-
Websitegeovax.com
Analyst ratings
Based on 1 analyst giving stock ratings to GOVX in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for GOVX in the last 3 months
Highest
Current 0,30 US$
10,00 US$ (+3 178,69%)
Average
10,00 US$ (+3 178,69%)
Lowest
10,00 US$ (+3 178,69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert LeBoyer
Noble Financial
Buy
Reiterated
10,00 US$
+3 178,7%
09/17/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
10,00 US$
+3 178,7%
05/26/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
02/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
5,04 მლნ.
2,99 მლნ.
3,90 მლნ.
3,11 მლნ.
Cost of revenue
5,04 მლნ.
2,99 მლნ.
3,90 მლნ.
3,11 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,33 მლნ.
1,45 მლნ.
1,37 მლნ.
1,33 მლნ.
Operating expense
1,33 მლნ.
1,45 მლნ.
1,37 მლნ.
1,33 მლნ.
Total operating expenses
6,37 მლნ.
4,44 მლნ.
5,27 მლნ.
4,44 მლნ.
Operating income
-6,37 მლნ.
-4,44 მლნ.
-5,27 მლნ.
-4,44 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-6,32 მლნ.
-4,42 მლნ.
-5,26 მლნ.
-4,43 მლნ.
EBT excluding unusual items
-6,32 მლნ.
-4,42 მლნ.
-5,26 მლნ.
-4,43 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6,32 მლნ.
-4,42 მლნ.
-5,26 მლნ.
-4,43 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
54,30 ათ.
23,33 ათ.
10,96 ათ.
15,49 ათ.
Interest expense
-
-
-
-
Net interest expenses
54,30 ათ.
23,33 ათ.
10,96 ათ.
15,49 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-6,36 მლნ.
-4,42 მლნ.
-5,26 მლნ.
-4,43 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები